People
are our inspiration
Home / People / NOMIS Researcher / Luregn Schlapbach

Luregn Schlapbach

Luregn Schlapbach

Loading...

NOMIS Project(s)

Luregn Schlapbach is head of the Pediatric and Neonatal Intensive Care Unit at the University Children’s Hospital Zurich (Switzerland) and holds the Professorship for Pediatric Intensive Care at the University of Zurich. He led the project Improving Recovery of Children Suffering from PIMS Associated with COVID (RECOVERY-PIMS), and is leading the Genomic and Immunologic Causes Underlying COVID-19 PIMS-TS and AI in Pediatric ICUs projects.

Schlapbach grew up in Zurich, Switzerland. In 2004 he received an MD from the University of Basel (Switzerland). He was trained in pediatrics, neonatology and pediatric intensive care in Switzerland and Australia. In 2013 he began working as senior staff specialist in pediatric intensive care in Australia, including at the country’s largest pediatric ICU at Queensland Children’s Hospital in Brisbane. Schlapbach has been leading the Department of Pediatric and Neonatal Intensive Care at the University Children’s Hospital Zurich since August 2020. He is also leading the Pediatric and Neonatal Intensive Care research group at the Children’s Research Center, University of Zurich, and maintains an active research program called Sepsis, Infection, and Inflammation in Critically Ill Children at the Child Health Research Centre at the University of Queensland. He has served as chair of the Australian and New Zealand Intensive Care Society Paediatric Study Group. He was group head of the Pediatric Surviving Sepsis Campaign and is co-chairman of the international Pediatric Sepsis Definition Taskforce. In recognition of his contribution to quality improvement initiatives for critically ill children, he was elected to the Global Sepsis Alliance executive committee.

Schlapbach’s research has focused on sepsis and life-threatening infections in critically ill neonates and children, including aspects such as epidemiology, sepsis markers, outcomes and genomics in this highly vulnerable patient group. He is interested in improving our understanding of why some children become critically unwell because of infections, and in developing better approaches to allow early recognition and targeted treatment of sepsis, severe infection and inflammation in children. He has been leading observational, genomic and interventional studies in the field, is involved in international consortia on life-threatening childhood infections, and serves on the steering board of several large pediatric trials.

Luregn Schlapbach | Awards Film

Luregn Schlapbach | Insights Film

Luregn Schlapbach's News

Led by NOMIS researcher Luregn Schlapbach, a group of over 40 national experts assembled a Swiss Sepsis National Action Plan. Enhancing innovative research that drives cutting-edge ideas from the bench […]

NOMIS researcher Luregn Schlapbach and colleagues have published a commentary in The Lancet Infectious Diseases, responding to recent findings that suggest the current treatment for neonatal sepsis in low- and […]

Luregn Schlapbach's Insights

Abstract: Background: Identifying phenotypes in sepsis patients may enable precision medicine approaches. However, the generalisability of these phenotypes to specific patient populations is unclear. Given that paediatric cancer patients with sepsis have different host response and pathogen profiles and higher mortality rates when compared to non-cancer patients, we determined whether unique,
Abstract: Purpose: Whilst survival in paediatric critical care has improved, clinicians lack tools capable of predicting long-term outcomes. We developed a machine learning model to predict poor school outcomes in children surviving intensive care unit (ICU). Methods: Population-based study of children < 16 years requiring ICU admission in Queensland, Australia, between 1997
Abstract:

Introduction: In 2020, a new disease entitled Pediatric Inflammatory Multisystem Syndrome temporally associated with COVID-19 (PIMS-TS), or Multisystem Inflammatory Syndrome in Children (MIS-C), emerged, with thousands of children affected globally. […]

Abstract:

Background: Following the spread of the coronavirus disease 2019 (COVID-19) pandemic a new disease entity emerged, defined as Pediatric Inflammatory Multisystem Syndrome temporally associated with COVID-19 (PIMS-TS), or Multisystem Inflammatory […]